Literature DB >> 30254215

Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression.

Małgorzata Rydzanicz1, Małgorzata Wachowska2, Erik C Cook3, Paweł Lisowski4,5, Bożena Kuźniewska6, Krystyna Szymańska7, Sebastian Diecke5, Alessandro Prigione5, Krzysztof Szczałuba1, Aleksandra Szybińska8, Agnieszka Koppolu1,9, Victor Murcia Pienkowski1,9, Joanna Kosińska1, Małgorzata Wiweger8, Grażyna Kostrzewa1, Małgorzata Brzozowska10, Dorota Domańska-Pakieła11, Elżbieta Jurkiewicz12, Piotr Stawiński1, Agnieszka Gromadka13, Piotr Zielenkiewicz13, Urszula Demkow2, Magdalena Dziembowska6, Jacek Kuźnicki8, Trevor P Creamer3, Rafał Płoski14.   

Abstract

PPP3CA encodes calmodulin-binding catalytic subunit of calcineurin, a ubiquitously expressed calcium/calmodulin-regulated protein phosphatase. Recently de novo PPP3CA variants were reported as a cause of disease in 12 subjects presenting with epileptic encephalopathy and dysmorphic features. We describe a boy with similar phenotype and severe early onset epileptic encephalopathy in whom a novel de novo c.1324C>T (p.(Gln442Ter)) PPP3CA variant was found by whole exome sequencing. Western blot experiments in patient's cells (EBV transformed lymphocytes and neuronal cells derived through reprogramming) indicate that despite normal mRNA abundance the protein expression level is strongly reduced both for the mutated and wild-type protein. By in vitro studies with recombinant protein expressed in E. coli we show that c.1324C>T (p.(Gln442Ter)) results in constitutive activation of the enzyme. Our results confirm the role of PPP3CA defects in pathogenesis of a distinct neurodevelopmental disorder including severe epilepsy and dysmorphism and provide further functional clues regarding the pathogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30254215      PMCID: PMC6303256          DOI: 10.1038/s41431-018-0254-8

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  24 in total

Review 1.  Calcineurin: form and function.

Authors:  F Rusnak; P Mertz
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

2.  The distal helix in the regulatory domain of calcineurin is important for domain stability and enzyme function.

Authors:  Tori B Dunlap; Erik C Cook; Julie Rumi-Masante; Hannah G Arvin; Terrence E Lester; Trevor P Creamer
Journal:  Biochemistry       Date:  2013-11-15       Impact factor: 3.162

3.  Stoichiometry of the calcineurin regulatory domain-calmodulin complex.

Authors:  Tori B Dunlap; Hou-Fu Guo; Erik C Cook; Emily Holbrook; Julie Rumi-Masante; Terrence E Lester; Christopher L Colbert; Craig W Vander Kooi; Trevor P Creamer
Journal:  Biochemistry       Date:  2014-08-29       Impact factor: 3.162

4.  Structural basis for activation of calcineurin by calmodulin.

Authors:  Julie Rumi-Masante; Farai I Rusinga; Terrence E Lester; Tori B Dunlap; Todd D Williams; A Keith Dunker; David D Weis; Trevor P Creamer
Journal:  J Mol Biol       Date:  2011-11-12       Impact factor: 5.469

5.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

6.  Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.

Authors:  C R Kissinger; H E Parge; D R Knighton; C T Lewis; L A Pelletier; A Tempczyk; V J Kalish; K D Tucker; R E Showalter; E W Moomaw
Journal:  Nature       Date:  1995-12-07       Impact factor: 49.962

7.  Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy?

Authors:  Rafal Ploski; Agnieszka Pollak; Sonja Müller; Maria Franaszczyk; Ewa Michalak; Joanna Kosinska; Piotr Stawinski; Mateusz Spiewak; Hubert Seggewiss; Zofia T Bilinska
Journal:  Circ Res       Date:  2014-01-17       Impact factor: 17.367

8.  The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin.

Authors:  Simina Grigoriu; Rachel Bond; Pilar Cossio; Jennifer A Chen; Nina Ly; Gerhard Hummer; Rebecca Page; Martha S Cyert; Wolfgang Peti
Journal:  PLoS Biol       Date:  2013-02-26       Impact factor: 8.029

Review 9.  Transient disorder: Calcineurin as an example.

Authors:  Trevor P Creamer
Journal:  Intrinsically Disord Proteins       Date:  2013-09-19

10.  Activation of calcineurin underlies altered trafficking of α2 subunit containing GABAA receptors during prolonged epileptiform activity.

Authors:  Ramona Eckel; Blanka Szulc; Matthew C Walker; Josef T Kittler
Journal:  Neuropharmacology       Date:  2014-09-22       Impact factor: 5.250

View more
  10 in total

1.  Aicardi-Goutières Syndrome due to a SAMHD1 Mutation Presenting with Deep White Matter Cysts.

Authors:  Barbara Oleksy; Hanna Mierzewska; Jolanta Tryfon; Maria Wypchło; Krystyna Wasilewska; Zofia Zalewska-Miszkurka; Rafał Płoski; Małgorzata Rydzanicz; Elżbieta Szczepanik
Journal:  Mol Syndromol       Date:  2021-11-18

2.  Severe Infantile Axonal Neuropathy with Respiratory Failure Caused by Novel Mutation in X-Linked LAS1L Gene.

Authors:  Agnieszka Stembalska; Małgorzata Rydzanicz; Wojciech Walas; Piotr Gasperowicz; Agnieszka Pollak; Victor Murcia Pienkowski; Mateusz Biela; Magdalena Klaniewska; Zuzanna Gamrot; Ewa Gronska; Rafal Ploski; Robert Smigiel
Journal:  Genes (Basel)       Date:  2022-04-21       Impact factor: 4.141

Review 3.  Identifying New Substrates and Functions for an Old Enzyme: Calcineurin.

Authors:  Jagoree Roy; Martha S Cyert
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

4.  Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report.

Authors:  Sai Yang; Xiang Shen; Qingyun Kang; Xiaojun Kuang; Zeshu Ning; Shulei Liu; Hongmei Liao; Zhenhua Cao; Liming Yang
Journal:  BMC Pediatr       Date:  2020-06-27       Impact factor: 2.125

5.  The Role of the Reanalysis of Genetic Test Results in the Diagnosis of Dysmorphic Syndrome Caused by Inherited xq24 Deletion including the UBE2A and CXorf56 Genes.

Authors:  Ewelina Wolańska; Agnieszka Pollak; Małgorzata Rydzanicz; Karolina Pesz; Magdalena Kłaniewska; Anna Rozensztrauch; Paweł Skiba; Piotr Stawiński; Rafał Płoski; Robert Śmigiel
Journal:  Genes (Basel)       Date:  2021-02-27       Impact factor: 4.096

6.  Further Delineation of Developmental Delay with Gastrointestinal, Cardiovascular, Genitourinary, and Skeletal Abnormalities Caused by ZNF699 Gene Mutation.

Authors:  Mateusz Biela; Malgorzata Rydzanicz; Agnieszka Jankowska; Agnieszka Szlagatys-Sidorkiewicz; Anna Rozensztrauch; Rafał Płoski; Robert Smigiel
Journal:  Genes (Basel)       Date:  2022-01-18       Impact factor: 4.096

7.  Investigation of Copy Number Variations (CNVs) of the Goat PPP3CA Gene and Their Effect on Litter Size and Semen Quality.

Authors:  Yangyang Bai; Taiyuan Zhang; Nuan Liu; Congliang Wang; Zhengang Guo; Chuanying Pan; Haijing Zhu; Xianyong Lan
Journal:  Animals (Basel)       Date:  2022-02-12       Impact factor: 2.752

8.  Case report: A novel PPP3CA truncating mutation within the regulatory domain causes severe developmental and epileptic encephalopathy in a Chinese patient.

Authors:  Jieling Li; Jie Cao
Journal:  Front Neurol       Date:  2022-09-07       Impact factor: 4.086

9.  Intracardiac tumor as a rare manifestation of genetic syndromes-presentation of a family with Gorlin syndrome and a literature review.

Authors:  Krzysztof Szczałuba; Ewa Makuła; Anna Piórecka-Makuła; Justyna Sicińska; Małgorzata Rydzanicz; Piotr Gasperowicz; Rafał Płoski; Bożena Werner
Journal:  J Appl Genet       Date:  2020-09-22       Impact factor: 3.240

10.  TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA.

Authors:  Zheng Wang; Haixia Li; Hongxia Wang; Xin Li; Qiong Zhang; Haifang Wang; Kui Li; Yurong Qiu
Journal:  Anticancer Drugs       Date:  2022-06-01       Impact factor: 2.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.